Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
Delayed Quote. Delayed Nyse - 10/23 04:10:00 pm
49.81 USD   -1.33%
10/23QIAGEN NV : Independant Research remains a Sell rating
MD
10/14QIAGEN NV : Kepler Cheuvreux maintains a Buy rating
MD
10/13QIAGEN NV : Jefferies remains Neutral
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

QIAGEN : to Launch Rapid Portable Test That Can Analyze Over 30 Samples Per Hour for SARS-CoV-2 Antigen

share with twitter share with LinkedIn share with facebook
09/08/2020 | 05:03pm EDT

  • Combination of speed and scale is an important step towards decentralized mass testing for coronavirus that has so far been elusive
  • Access Anti-SARS-CoV-2 Antigen Test, developed in collaboration with Ellume, is easy to use and provides accurate results in less than 15 minutes
  • Complements QIAGEN’s antibody and PCR tests to provide full range of COVID-19 testing solutions
  • Each Digital eHub device with capacity for up to 8 eSticks can simultaneously run QIAGEN Access Antigen and Antibody tests

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to launch a rapid portable test that can detect SARS-CoV-2 antigens in people with active infections in less than 15 minutes and process on average around 30 swab samples per hour using a small digital detection system.

The Access Anti-SARS-CoV-2 Antigen Test, which is expected to become available in the fourth quarter of 2020, is designed for environments that require a high volume of fast and accurate test results. The portable test offers a new combination of speed and scale that marks an important step towards decentralized mass testing that health authorities all over the world have been urgently seeking.

The Access Anti-SARS-CoV-2 Antigen Test extends the partnership with Ellume, an Australian digital diagnostics company. It is the second QIAGEN COVID-19 test to make use of Ellume’s digital eHub and eStick system. QIAGEN in August announced the Access Anti-SARS-CoV-2 Antibody Test that uses the same devices.

Two versions of the Antigen Test are scheduled for US launch in the fourth quarter – one for labs and one for point-of-care (POC) use. QIAGEN will apply for FDA Emergency Use Authorization and seek CE-IVD registration in Europe. A CLIA Waiver in the US would allow the POC version to be used in settings like airports or stadiums.

Feasibility tests have shown the Access Antigen Test to have a sensitivity of at least 90% and a specificity of 100%.

Please find the full press release here.

Further information on QIAGEN’s response to the coronavirus outbreak can be found here.

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about QIAGEN N.V.
10/23QIAGEN NV : Independant Research remains a Sell rating
MD
10/14QIAGEN NV : Kepler Cheuvreux maintains a Buy rating
MD
10/13QIAGEN NV : Jefferies remains Neutral
MD
10/13QIAGEN N : reports strong preliminary results for third quarter of 2020
BU
10/13QIAGEN N.V. : QIAGEN reports strong preliminary results for third quarter of 202..
EQ
10/09QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
10/05QIAGEN : to Complement COVID-19 Testing Portfolio With Novel Kit That Simplifies..
BU
09/18QIAGEN NV : Warburg Research reiterates its Neutral rating
MD
09/17QIAGEN N : fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR..
BU
09/15QIAGEN NV : DZ Bank reiterates its Neutral rating
MD
More news
Financials (USD)
Sales 2020 1 802 M - -
Net income 2020 326 M - -
Net Debt 2020 1 017 M - -
P/E ratio 2020 35,6x
Yield 2020 -
Capitalization 11 394 M 11 394 M -
EV / Sales 2020 6,89x
EV / Sales 2021 5,93x
Nbr of Employees 5 200
Free-Float 92,9%
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 55,82 $
Last Close Price 49,81 $
Spread / Highest target 32,5%
Spread / Average Target 12,1%
Spread / Lowest Target -23,7%
EPS Revisions
Managers
NameTitle
Thierry Bernard Chief Executive Officer
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.47.37%11 394
LONZA GROUP AG62.80%47 152
SEAGEN INC.72.54%34 263
IQVIA HOLDINGS INC.8.39%32 108
CELLTRION, INC.31.49%28 160
MODERNA, INC.260.58%27 830